H.C. Wainwright analyst Kevin Dede reiterated a Buy rating on Biotricity (BTCY – Research Report) today and set a price target of $2.00. The company’s shares closed yesterday at $1.20.
According to TipRanks, Dede is an analyst with an average return of -4.2% and a 34.31% success rate. Dede covers the Technology sector, focusing on stocks such as HIVE Blockchain Technologies, Biotricity, and Voyager Digital (Canada).
Biotricity has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.
See Insiders’ Hot Stocks on TipRanks >>
BTCY market cap is currently $62.12M and has a P/E ratio of -1.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biotricity, Inc. engages in the provision of biometric data monitoring solutions. The firm offers the Bioflux, a single-unit mobile cardiac telemetry device. It also develops Biolife, which is intended for chronic disease prevention. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.
Read More on BTCY:
- TOMI Environmental Solutions (TOMZ) Receives a Rating Update from a Top Analyst
- Verde announces strategic sales partnership with Lavoro, Latin America’s largest distributor of agricultural inputs
- thredUP (TDUP) Receives a Buy from Needham
- Arbe Announces Q2 2022 Financial Results
- Tremor International Reports Results for the Second Quarter and Six-Month Period Ended June 30, 2022
